A one-minute look at managed care news during the week of March 2, 2015, including oral arguments for King v. Burwell and the approval of the first biosimilar in the United States.
The Supreme Court of the United States heard oral arguments for King v. Burwell this week, and at the end of the hearing the justices were clearly divided about the legality of tax subsidies for consumers on the federally facilitated marketplace.
In oncology news, the US now has its first biosimilar with the FDA approval of Sandoz’s Zarxio for some cancer patients, plus the National Cancer Institute’s director is stepping down.
Finally, The American Journal of Managed Care convened a panel of experts to discuss the role of formulary management in the changing dynamics for hepatitis C. Listen to the panel discussion here.
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients
August 15th 2025The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.
Read More
PCPs Have Unique Opportunity to Detect, Manage CKD
August 14th 2025As the prevalence of chronic kidney disease (CKD) continues to rise, empowering primary care providers (PCPs) with the tools, training, and collaborative frameworks needed for optimal management is a public health priority, emphasize the researchers.
Read More